Drugs / LS301-IT
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06713564 | Nov 2024 → May 2026 | lung cancer | Integro Theranostics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05900986 | Jul 2023 → Oct 2025 | ductal breast carcinoma in situ, female breast carcinoma, invasive ductal breast carcinoma | Integro Theranostics | Completed | No outcome recorded |
| Phase 1/2 | NCT04105062 | Dec 2021 → Dec 2023 | gastric cancer, gastrointestinal stromal tumor, liver cancer, malignant pancreatic neoplasm +1 | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02807597 | Feb 2020 → Jan 2022 | breast cancer | Samuel Achilefu | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT07276789 | Dec 2025 → Aug 2026 overdue | non-small cell lung carcinoma | Integro Theranostics | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LS301-IT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07276789 ↗ |
| Known as | LS301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04105062 ↗ |
| Modality | Small molecule | “LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.” NCT02807597 ↗ |
| Route | Intravenous | “LS301 will be administered intravenously” NCT02807597 ↗ |
| Target | ANXA2 | “binds phosphorylated Annexin A2 (ANXA2)” NCT06713564 ↗ |